Post-treatment level of LDL-C and all-cause mortality in patients with atherosclerotic cardiovascular disease: evidence from real-world setting.

This study aimed to evaluate the safety of currently recommended target of LDL-C control on mortality in patients with atherosclerotic cardiovascular disease (ASCVD). Using deidentified electronic health record data, we conducted a multicenter retrospective cohort study involving individuals with documented ASCVD who had received statin treatment for at least 3 months across China. The primary outcomes assessed encompassed all-cause mortality, cardiovascular mortality, and non-cardiovascular mortality. Relationships between post-treatment LDL-C concentrations and outcomes were evaluated using restricted cubic spline (RCS) curves based on Cox proportional hazards regression analyses. Additionally, competitive risk models were employed to explore associations between LDL-C levels and cause-specific mortality. Among 33,968 participants, we identified nearly linear associations of post-treatment LDL-C level with all-cause mortality and CV mortality during a median follow-up of 47 months. Notably, patients who achieved the recommended target of LDL-C (<1.4 mmol/L) were at significant lower risks of all-cause mortality (HR, 0.77; 95%CI, 0.69-0.86) and CV mortality (sHR, 0.68; 95%CI, 0.58-0.79), compared with those with LDL-C ≥ 3.4 mmol/L. This survival benefit was consistent in patients with different intensity of LDL-C reduction and other subgroup analyses. And no correlation was found between post-treatment LDL-C concentration and non-CV mortality. Our findings supported the safety of currently recommended target of LDL-C control and the "lower is better" principle in patients with ASCVD. Intensive control of low-density lipoprotein-cholesterol (LDL-C) has been widely recommended for cardiovascular (CV) protection in patients with ASCVD. Nevertheless, a U-shaped association between LDL-C levels and all-cause mortality has been noted in several general population studies, prompting concerns regarding the safety of intensive lipid control. In this multicenter cohort comprising 33,968 patients at the highest cardiovascular risk, we found that patients with lower post-treatment LDL-C level were at lower risk of both all-cause and CV mortality, and this survival benefit was unaffected by intensity of LDL-C reduction, types of lipid-lowering agents and other clinical characteristics.

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For permissions, please e-mail: [e-mail].